CRISPR/Cas-powered nanobiosensors for diagnostics

CRISPR diagnostics (CRISPR-Dx) offer a wide range of enhancements compared to traditional nanobiosensors by taking advantage of the excellent trans-cleavage activity of the CRISPR/Cas systems. However, the singlestranded DNA/RNA reporters of the current CRISPR-Dx suffer from poor stability and limited sensitivity, which make their application in complex biological environments difficult. In comparison, nanomaterials, especially metal nanoparticles, exhibits robust stability and desirable optical and electrocatalytical properties, which make them ideal as reporter molecules. Therefore, biosensing research is moving towards the use of the trans-cleavage activity of CRISPR/Cas effectors on metal nanoparticles and apply the new phenomenon to develop novel nanobiosensors to target various targets such as viral infections, genetic mutations and tumor biomarkers, by using different sensing methods, including, but not limited to fluorescence, luminescence resonance, colorimetric and electrochemical signal readout. In this review, we explore some of the most recent advances in the field of CRISPR-powered nanotechnological biosensors. Demonstrating high accuracy, sensitivity, selectivity and versatility, nanobiosensors along with CRISPR/Cas technology offer tremendous potential for next-generation diagnostics of multiple targets, especially at the point of care and without any target amplification.

Automated summary

CRISPR-Dx offers broad enhancements compared to traditional nanobiosensors by utilizing the trans-cleavage activity of the CRISPR/Cas systems. However, the current singlestranded DNA/RNA reporters of CRISPR-Dx have poor stability and limited sensitivity. Research is shifting towards using the trans-cleavage activity of CRISPR/Cas effectors on metal nanoparticles to develop novel nanobiosensors with high accuracy, sensitivity, selectivity, and versatility.